| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $2,000,000 | 1 | 100 |
Sells | $0 | 0 | 0 |
| ORBIMED ADVISORS LLC | 10 percent owner | 1 | $2M | 0 | $0 | $2M |
scPharmaceuticals Inc., a pharmaceutical company, engages in the development and commercialization of various pharmaceutical products. The company's lead product candidate is FUROSCIX that consists of formulation of furosemide, which is delivered through an on-body infusor for treatment of congestion in patients with heart failure. Its product pipeline also includes scCeftriaxone, an antibiotic to treat infections caused by gram-positive and gram-negative organisms; and scCarbapenem program, an antibiotic for treating infections caused by gram-negative organisms. The company has a development agreement with West Pharmaceutical Services, Inc. for development of single use SmartDose device. scPharmaceuticals Inc. was incorporated in 2013 and is headquartered in Burlington, Massachusetts.
Over the last 12 months, insiders at scPharmaceuticals Inc. have bought $2M and sold $0 worth of scPharmaceuticals Inc. stock.
On average, over the past 5 years, insiders at scPharmaceuticals Inc. have bought $2.02M and sold $1.56M worth of stock each year.
Highest buying activity among insiders over the last 12 months: ORBIMED ADVISORS LLC (10 percent owner) — $2M.
The last purchase of 500,000 shares for transaction amount of $2M was made by ORBIMED ADVISORS LLC (10 percent owner) on 2024‑08‑13.
| 2024-08-13 | ORBIMED ADVISORS LLC | 10 percent owner | 500,000 1.2438% | $4.00 | $2M | -28.80% | ||
| 2022-11-25 | ORBIMED ADVISORS LLC | director | 762,380 1.7007% | $5.25 | $4M | +2.06% | ||
| 2022-10-10 | Sale | Schwab Andrew J. | director | 562,466 1.831% | $4.09 | $2.3M | +91.04% | |
| 2022-10-06 | Sale | Schwab Andrew J. | director | 37,534 0.1225% | $5.02 | $188,421 | +56.10% | |
| 2022-09-06 | Sale | Schwab Andrew J. | 6,793 0.022% | $4.75 | $32,267 | +43.28% | ||
| 2022-04-11 | Sale | Schwab Andrew J. | 220,096 0.776% | $5.00 | $1.1M | +10.62% | ||
| 2021-12-03 | Tucker John H | President and CEO | 10,000 0.0373% | $3.96 | $39,553 | +30.15% | ||
| 2021-12-03 | Khattar Jack A. | director | 5,000 0.0184% | $3.91 | $19,569 | +30.15% | ||
| 2021-03-15 | Sale | RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 110,588 0.3963% | $7.03 | $777,788 | -20.33% | |
| 2021-03-12 | Sale | RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 39,469 0.1461% | $7.22 | $284,816 | -19.78% | |
| 2020-05-26 | Schwab Andrew J. | 10 percent owner | 578,034 2.5395% | $8.65 | $5M | -12.34% | ||
| 2020-05-21 | ORBIMED ADVISORS LLC | 10 percent owner | 1.39M 6.0411% | $8.65 | $12M | -12.99% | ||
| 2020-02-14 | RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 271,993 1.2768% | $8.20 | $2.23M | -7.06% | ||
| 2019-12-13 | Tucker John H | President and CEO | 5,000 0.0266% | $5.24 | $26,189 | +52.26% | ||
| 2019-04-11 | RA CAPITAL MANAGEMENT, LLC | 10 percent owner | 389,862 2.1623% | $2.70 | $1.05M | +109.92% | ||
| 2017-11-21 | ORBIMED ADVISORS LLC | 10 percent owner | 833,333 9.7286% | $14.00 | $11.67M | -28.96% | ||
| 2017-11-21 | Lundbeckfond Invest A/S | 10 percent owner | 1.31M 15.2879% | $14.00 | $18.33M | -28.96% | ||
| 2017-11-21 | Agger Mette Kirstine | 1.31M 15.2879% | $14.00 | $18.33M | -28.96% | |||
| 2017-11-21 | 5AM Partners IV, LLC | 10 percent owner | 1.31M 7.6439% | $7.00 | $9.17M | -28.96% | ||
| 2017-11-21 | SUN PHARMACEUTICAL INDUSTRIES LTD | 10 percent owner | 714,286 8.3388% | $14.00 | $10M | -28.96% |
| ORBIMED ADVISORS LLC | 10 percent owner | 5806670 10.9991% | $25.43M | 4 | 0 | <0.0001% |
| Lundbeckfond Invest A/S | 10 percent owner | 3183986 6.0312% | $13.95M | 1 | 0 | <0.0001% |
| Agger Mette Kirstine | 3183986 6.0312% | $13.95M | 1 | 0 | <0.0001% | |
| 5AM Partners IV, LLC | 10 percent owner | 3123302 5.9162% | $13.68M | 1 | 0 | <0.0001% |
| RA CAPITAL MANAGEMENT, L.P. | 10 percent owner | 2727446 5.1664% | $11.95M | 2 | 2 | +51.43% |
| SUN PHARMACEUTICAL INDUSTRIES LTD | 10 percent owner | 357143 0.6765% | $1.56M | 1 | 0 | <0.0001% |
| Schwab Andrew J. | director | 92983 0.1761% | $407,265.54 | 1 | 4 | <0.0001% |
| Tucker John H | President and CEO | 46962 0.089% | $205,693.56 | 2 | 0 | +41.21% |
| Khattar Jack A. | director | 5000 0.0095% | $21,900.00 | 1 | 0 | +30.15% |
$54,762,250 | 63 | -1.52% | $235.21M | |
$613,304,943 | 46 | 11.85% | $239.02M | |
$2,545,071 | 34 | 16.59% | $247.71M | |
$63,049,419 | 31 | 2.87% | $208.65M | |
$74,231,875 | 30 | 40.62% | $248.59M | |
$79,019,806 | 27 | 7.24% | $216.41M | |
$46,858,891 | 18 | -11.58% | $222.53M | |
$17,594,514 | 16 | -20.37% | $255.76M | |
$12,110,219 | 14 | 336.38% | $225.47M | |
scPharmaceuticals Inc. (SCPH) | $91,870,774 | 13 | 3.64% | $231.23M |
$15,799,576 | 12 | -39.52% | $204.8M | |
$1,229,070 | 10 | 23.53% | $213.86M | |
$6,847,110 | 9 | 5.96% | $241.09M | |
$5,905,507 | 7 | 2.69% | $245.66M | |
$8,286,963 | 6 | 3.09% | $242.49M | |
$88,549,962 | 5 | -16.91% | $198.27M | |
$4,460 | 2 | 29.08% | $219.49M | |
$879,499 | 1 | 28.50% | $245.95M | |
$9,999,990 | 1 | 32.51% | $211.66M |
| Increased Positions | 44 | +46.32% | 3M | +6.35% |
| Decreased Positions | 39 | -41.05% | 5M | -13.66% |
| New Positions | 12 | New | 1M | New |
| Sold Out Positions | 11 | Sold Out | 2M | Sold Out |
| Total Postitions | 100 | +5.26% | 37M | -7.3% |
| Orbimed Advisors Llc | $15,755.00 | 12.12% | 6.06M | 0 | 0% | 2024-12-31 |
| Rubric Capital Management Lp | $12,415.00 | 9.55% | 4.78M | 0 | 0% | 2024-12-31 |
| Aigh Capital Management Llc | $10,853.00 | 8.35% | 4.17M | +50,000 | +1.21% | 2024-12-31 |
| King Luther Capital Management Corp | $7,431.00 | 5.72% | 2.86M | +632,120 | +28.4% | 2024-12-31 |
| Blackrock, Inc. | $6,128.00 | 4.71% | 2.36M | +73,639 | +3.23% | 2025-03-31 |
| Vanguard Group Inc | $5,482.00 | 4.22% | 2.11M | +399,511 | +23.38% | 2024-12-31 |
| Morgan Stanley | $4,966.00 | 3.82% | 1.91M | +2M | +474.2% | 2024-12-31 |
| Suvretta Capital Management, Llc | $4,786.00 | 3.68% | 1.84M | -208,118 | -10.16% | 2024-12-31 |
| Rice Hall James & Associates, Llc | $3,635.00 | 2.8% | 1.4M | +408,422 | +41.27% | 2025-03-31 |
| J. Goldman & Co Lp | $3,170.00 | 2.44% | 1.22M | -160,866 | -11.66% | 2024-12-31 |